Live From ASCO, Cybrexa is Featured on OncologyTube-How Does alphalex Work?

https://www.oncologytube.com/video/what-is-alphalex-how-does-it-work-makes-use-of-acidic-tumor-environment-to-deliver-anti-cancer-agents-directly-into-the-tumor/10006441

https://www.oncologytube.com/video/how-is-alphalex-different-its-an-antigen-agnostic-tumor-targeting-technology-can-target-almost-any-solid-tumor-in-theory/10006439

 

 

Cybrexa Therapeutics in Pharma Technology Focus

Cybrexa, a spin-out company from Yale University, is developing a new class of cancer therapeutics, looking to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity in cancer treatment. Abi Millar spoke to the company to find out more about its approach to oncology.

Read More

Cybrexa Therapeutics in BioWorld

Cybrexa Therapeutics, a New Haven, Conn.-based company developing a solid tumor-targeting technology to work with an already-approved PARP inhibitor, said it plans to submit an investigational new drug application for its lead candidate, CBX-11, by the fourth quarter of 2019. A phase I trial evaluating the drug is expected to begin in the first quarter of 2020. If preclinical findings hold, the approach could potentially enhance the therapeutic index of the PARP inhibitor, improve overall survival and limit the toxicities associated with combining PARP inhibitors and DNA-damaging chemotherapy.

View the PDF

Cybrexa featured in BioCentury Innovations

CYBREXA: PH-BASED TUMOR TARGETING

By Chris Lieu, Staff Writer

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors.

Cybrexa uses its alphalex technology to conjugate a cancer agent to a pH-sensitive peptide via an undisclosed linker. The peptide forms a transmembrane α-helix only at a low pH, which occurs in the tumor microenvironment but not normal tissues, and translocates into cells along with its cargo via a non-endocytotic route. Cytoplasmic glutathione cleaves the linker, releasing the free cancer agent inside the cancer cell.

Cybrexa has applied the alphalex technology to PARP inhibitors first because in DNA damage response (DDR)-proficient cancers, PARP inhibitors are most effective in combination with chemotherapy, but the combination leads to toxicities including myelosuppression, nephrotoxicity and hepatotoxicity, said President and CEO Per Hellsund.

View the PDF here.

Cybrexa Therapeutics in the Hartford Courant

Aug 22, 2017 

“It’s really like a heat-seeking missile toward tumors,” Yale physician-scientist and Cybrexa’s chief scientific adviser, Dr. Ranjit Bindra, tells the Hartford Courant. “I know it sounds over the top but we’re really re-writing the rules of what makes a drug good and what drugs are possible to deliver to humans.”

Dr. Ranjit Bindra, co-founder of Cybrexa, and Per Hellsund, President and CEO, sat down with the Hartford Courant to discuss the venture’s origins and technology. Read the full article (and watch the video) HERE.